Working… Menu

Cisplatin in Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03275857
Recruitment Status : Recruiting
First Posted : September 8, 2017
Last Update Posted : March 18, 2020
Roswell Park Cancer Institute
Information provided by (Responsible Party):
Deepak Sahasrabudhe, University of Rochester

Brief Summary:
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Cisplatin Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide
Actual Study Start Date : September 21, 2018
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Cisplatin

Arm Intervention/treatment
Cisplatin Drug: Cisplatin
Weekly IV

Primary Outcome Measures :
  1. Response to dosing differences of Cisplatin from lab and scan results [ Time Frame: 2 years ]
    Measures of response will be decline in Prostate Specific Antigen (PSA) and regression of metastases.

  2. Toxicity observed with dosing differences of Cisplatin [ Time Frame: 2 years ]
    Blood samples and physical assessments will be conducted and reviewed to determine toxicity of treatment. Toxicity would be symptoms such as ringing in the ears (tinnitus) peripheral neuropathy or lab findings such as rise in creatinine, electrolyte abnormalities such as low magnesium.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic diagnosis of prostate cancer
  • Age 18 yrs or older
  • Able to provide written, informed consent
  • Subjects who have received docetaxel for metastatic disease are eligible if absolute neutrophil count is greater than 100 and platelet count is greater than 100,000 and their bone marrow reserve is deemed to be adequate
  • Subjects with castration resistant prostate cancer, as defined by having testosterone level of less than 50 Nano gram/dl, being treated with enzalutamide with a rise in PSA, confirmed with a repeat measurement within 1 to four weeks, or asymptomatic radiographic progression

Exclusion Criteria:

  • Subjects with estimated glomerular filtration rate of less than 50 ml/min
  • Subjects with hearing impairment. The treating physician may decide which subjects should not receive cisplatin based on audiometry or based on clinical judgment.
  • Subjects with grade 2 or greater neuropathy
  • Subjects who in the opinion of the treating physician could not tolerate the standard hydration before receiving cisplatin
  • Chemotherapy naïve subjects who in the opinion of the treating physician should receive docetaxel instead of enrolling on the trial and receive cisplatin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03275857

Layout table for location contacts
Contact: Ayesha Khan 5852755531

Layout table for location information
United States, New York
Wilmot Cancer Institute Recruiting
Rochester, New York, United States, 14642
Contact: Ayesha Khan    585-275-3351   
Sponsors and Collaborators
University of Rochester
Roswell Park Cancer Institute
Layout table for additonal information
Responsible Party: Deepak Sahasrabudhe, Professor, University of Rochester Identifier: NCT03275857    
Other Study ID Numbers: UGUP-17050
First Posted: September 8, 2017    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Antineoplastic Agents